Drug intelligence / Profile preview

AN9015

Development stage: Preclinical
Lead developer: Hangzhou Adlai Nortye Biopharma
Modality: Small Molecules

Overview

**AN9015** is a small molecule drug developed by Hangzhou Adlai Nortye Biopharma Co. Ltd. that acts as a modulator of **CSF-1R** (colony stimulating factor 1 receptor) and an inhibitor of **c-Kit** (stem cell growth factor receptor). These targets are implicated in tumor-associated macrophages and tumor cell proliferation, respectively, supporting its potential in oncology. It is in **preclinical development** for neoplasms, with rights licensed worldwide to Xiamen Biotime Biotechnology Co., Ltd. in 2022.

Targets

KIT (c-KIT proto-oncogene receptor tyrosine kinase)CSF1R (Macrophage colony-stimulating factor receptor)

Beyond the preview

Go deeper on AN9015.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AN9015.

Explore the full profile